Biora Therapeutics (NASDAQ:BIOR) Price Target Raised to $23.00 at HC Wainwright

Biora Therapeutics (NASDAQ:BIOR) had its target price increased by HC Wainwright from $15.00 to $23.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Biora Therapeutics Stock Down 9.9 %

Shares of NASDAQ BIOR opened at $1.63 on Monday. Biora Therapeutics has a twelve month low of $1.55 and a twelve month high of $19.90. The company’s fifty day moving average is $4.64 and its 200-day moving average is $6.00. The stock has a market cap of $7.37 million, a price-to-earnings ratio of -0.13 and a beta of 1.27.

Biora Therapeutics Company Profile

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.